All assets

ELI LILLY & Co (LLY)

equity · NYSE

Last 30 days
11 mentions · 10 episodes
Last 90 days
11 mentions · 10 episodes

Stance shows how speakers talked about the asset, not investment advice. Figures and views are speaker claims; verify them against the original audio and primary sources.

Mentions over time

bullishbearishmixedneutral
2026-08-24
2026-08-31
2026-09-07
2026-09-14
2026-09-21
2026-09-28
2026-10-05
2026-10-12
2026-10-19
2026-10-26
2
2026-11-02
14
2026-11-09
4
2026-11-16

Recent mentions

  1. The Truth About Money with Bruce Weinstein ·

    Pension Choices and the Two Values on an Annuity Statement

    Unidentified speaker (speaker_1) neutral

    “Nvidia, Apple, Microsoft, Alphabet, Google, Amazon, Broadcom, Met Meta, which is used to be Facebook, Tesla. Eli Lilly, Micron. And those 10 combined control 39.8% of the market returns.”

    Listen at 2:43Original audio

  2. Mad Money w/ Jim Cramer ·

    Mad Money: Wall Street Jargon, Cyclicals, GARP & Corrections 11/13/26

    Unidentified speaker (speaker_3) neutral

    “the drug stocks like Pfizer or Merck or Eli Lilly.”

    Listen at 6:11Original audio

  3. CNBC's "Fast Money" ·

    Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven Surge 11/12/26

    Unidentified speaker (speaker_3) neutral

    “The company announcing that it will have the first GLP and one weight loss pill approved in China. Uh Regulators previously only improved approved uh injectable GLP GLP1 100%. medications for weight loss there. Lily is now up 33% this year.”

    Listen at 29:05Original audio

  4. Brew Markets ·

    Huang Affair Rocks Nvidia & Tesla Shifts Gears

    John Croteau neutral

    “And finally, shares of Eli Lilly gained more than 4% after the company said its weight loss pill Foundado helped reduce sleep apnea for patients with obesity.”

    Listen at 21:15Original audio

  5. Equity Mates Investing Podcast ·

    Our Monthly Portfolio Update - October 2026

    Unidentified speaker (speaker_0) neutral

    “That that would be my only watch at the moment for Eli Lilly.”

    Listen at 26:51Original audio

  6. The Compound and Friends ·

    You Ain’t Seen Nothing Yet with Daniel Clifton

    Unidentified speaker neutral

    “they're looking for secular growth opportunities and they're finding them in pharma, Eli Lilly, Biotech, um, all of the life sciences equipment, uh, the AI-related healthcare stuff that's like gonna speed up drive stuff.”

    Listen at 1:00:01Original audio

  7. Art of Boring ·

    Consumer Biotech: The Value Chain Beneath the GLP-1 Boom | EP 234

    Unidentified speaker (speaker_0) neutral

    “Eli Lilly's stock price has been on tear for several years.”

    Listen at 5:01Original audio

  8. In the Money with Amber Kanwar ·

    The Midterms, the Markets and a Surprising Opportunity in Healthcare

    Unidentified speaker bullish

    “Now, in this more recent cycle, it really comes down to Eli Lilly, which we own.”

    Listen at 16:05Original audio

  9. Mad Money w/ Jim Cramer ·

    Mad Money w/ Jim Cramer 11/3/26

    Unidentified speaker (speaker_1) neutral

    “Absolutely. Um, my question is about Eli Lilly. I took my first small position last month and it's up about eleven percent.”

    Listen at 18:27Original audio

  10. The Pomp Podcast ·

    Bitcoin Survives Biggest Crypto Hack In History?! | Jordi Visser

    Unidentified speaker bullish

    “First of all, the numbers are stagnant. Um, I I challenge anyone to just go into an LLM and say, hey, can you give me the earnings details from this quarter for Eli Lilly? I mean, you're talking about revenue growth. Revenue. So to give people an idea, like good revenue, the SP 500 right now, revenue growth is about 12%. And that's probably where we're gonna finish, which is less than it was in Q2. Eli Lilly's revenue growth year over year is 40%. Um 20 24.4 billion dollars. Let me just read some of these notes. These are so crazy. So Eli Lilly reported revenue of $24.4 billion up 39%. The expectation was $22.6 billion. So they outperformed expectations by $2 billion or almost 10%. Their volume grew 53%, uh prices are down 15%, gross margin was 83%, non-gap EPS was $7.48 against a $6.26 uh cent. So they beat non-gap EPS by over a dollar. Pretty incredible. And uh Munjaro brought in $10 billion, which is up 65%, and Zipbound brought in $5 billion, which is up 50%. And then they basically look at their 2026 revenue guidance rose. They think that it's going to be $91 to $92 billion, where previously they were reporting $85 to $87. So somewhere in the ballpark of six or seven billion dollars additional revenue guidance. And uh about yeah, and so they're growing at you know $90 billion run rate. They're still growing revenue at 40% year over year.”

    Listen at 39:49Original audio

  11. The Pomp Podcast ·

    Bitcoin Survives Biggest Crypto Hack In History?! | Jordi Visser

    Unidentified speaker bullish

    “So NVIDIA's stuck in mud, their PE has collapsed. Um they announced 70% revenue growth. Their PE is down at 13, 12. Who knows whether it's that making more bullish on NVIDIA? No. No. And here's the reason why. There are two things about Eli Lilly comparing them to NVIDIA that are very different. Number one, the great thing about Eli Lilly in this world of AI infrastructure trades, they are making money on the healthcare problems in the United States where the spending is coming, is guaranteed every year. It is non-cyclical. So they've historically, because they didn't have these growth numbers for a pharmaceutical company are insane. Now, most of this is related to obesity, but the penetration that they've had, remember, this has been an injectable. Now they're moving to an oral. They have about 10% of people, from what I saw in the thing, diagnosed with obesity in the US. They've only penetrated 10% at this point, which means they still have a lot of room, especially with pills. The prices are going down, their volumes are going faster than their price decline. You love to see that. I think they've called that Jevins paradox. I don't really know. But as the price goes lower and more coverage happens, go. Globally, this is that was just the US numbers, but globally they are less than I think 3%. I think it's 2% of the global. So they still have more money from that. And that's where most of their growth is coming from. But when you go through the other areas like dementia, oncology, immunology, they've got significant revenue growth there. And what people have to understand is it's one thing to be dealing with just obesity and diabetes. It's another thing to have this growth area that is also there from all of the drug discovery that they're spending time on. That stuff is going to be down the road. I love having call options. If they come up with some cure on something, what happened to Moderna when they came through with something that's still up for debate? You get this massive rise because they start building in the numbers. So you have the non-cyclicality, which means it's a diversification on the other things. I'm sitting here, I say, okay, my biggest position is X, you know, I my biggest position was Morvell. Well, then it just fell 20%. My biggest position is now Eli Lilly because it went up 10%. Regardless, Eli Lilly has been unbelievable. And all of this is happening as it's about to post its 10th positive year in a row. And this one will be another 30%. So it's been compounding in this very steady fashion on the back of the diabetes situation, but they've got a lot more call options with inside their numbers.”

    Listen at 41:59Original audio

Claims about this asset

No linked claims yet.

    Often mentioned with

    Podcasts that cover it most

    1. Mad Money w/ Jim Cramer · 2 mentions
    2. The Pomp Podcast · 2 mentions
    3. The Truth About Money with Bruce Weinstein · 1 mentions
    4. CNBC's "Fast Money" · 1 mentions
    5. Brew Markets · 1 mentions
    6. Equity Mates Investing Podcast · 1 mentions
    7. The Compound and Friends · 1 mentions
    8. Art of Boring · 1 mentions
    9. In the Money with Amber Kanwar · 1 mentions